| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| +0.75% | +1.43% | +7.13% | +83.44% | 45.63B | |
| -0.20% | -3.59% | +40.67% | +83.59% | 33.53B | |
| +0.44% | -0.85% | -7.55% | +44.74% | 11.81B | |
| -0.11% | +1.44% | +12.86% | +116.61% | 11.69B | |
| +0.59% | +0.78% | +36.70% | +126.43% | 9.12B | |
| +2.40% | +0.08% | +17.77% | +43.22% | 7.16B | |
| -1.12% | -0.56% | +41.74% | -17.87% | 6.49B | |
| +1.37% | +0.35% | +32.58% | +240.43% | 6.45B | |
| +0.51% | -3.04% | -42.24% | -5.52% | 5.16B | |
| Average | +0.44% | -0.16% | +15.52% | +79.45% | 15.23B | |
| Weighted average by Cap. | +0.42% | -0.28% | +18.06% | +82.98% |
Employees
2,191
Sector
Pharmaceuticals
